Literature DB >> 22641162

Prostate cancer: celecoxib trampled in the STAMPEDE trial.

Elaine T Lam, Thomas W Flaig.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22641162     DOI： 10.1038/nrurol.2012.112

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

Review 1.  Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention.

Authors:  Joseph W Basler; Gary A Piazza
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

2.  Celecoxib for the prevention of sporadic colorectal adenomas.

Authors:  Monica M Bertagnolli; Craig J Eagle; Ann G Zauber; Mark Redston; Scott D Solomon; KyungMann Kim; Jie Tang; Rebecca B Rosenstein; Janet Wittes; Donald Corle; Timothy M Hess; G Mabel Woloj; Frédéric Boisserie; William F Anderson; Jaye L Viner; Donya Bagheri; John Burn; Daniel C Chung; Thomas Dewar; T Raymond Foley; Neville Hoffman; Finlay Macrae; Ronald E Pruitt; John R Saltzman; Bruce Salzberg; Thomas Sylwestrowicz; Gary B Gordon; Ernest T Hawk
Journal:  N Engl J Med       Date:  2006-08-31       Impact factor: 91.245

3.  Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.

Authors:  Urs E Studer; Peter Whelan; Walter Albrecht; Jacques Casselman; Theo de Reijke; Dieter Hauri; Wolfgang Loidl; Santiago Isorna; Subramanian K Sundaram; Muriel Debois; Laurence Collette
Journal:  J Clin Oncol       Date:  2006-04-20       Impact factor: 44.544

4.  STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.

Authors:  N D James; M R Sydes; N W Clarke; M D Mason; D P Dearnaley; J Anderson; R J Popert; K Sanders; R C Morgan; J Stansfeld; J Dwyer; J Masters; M K B Parmar
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-08-29       Impact factor: 4.126

5.  Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.

Authors:  Matthew R Smith; Judith Manola; Donald S Kaufman; William K Oh; Glenn J Bubley; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

6.  Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study.

Authors:  Anne-Marie Schjerning Olsen; Emil L Fosbøl; Jesper Lindhardsen; Fredrik Folke; Mette Charlot; Christian Selmer; Morten Lamberts; Jonas Bjerring Olesen; Lars Køber; Peter R Hansen; Christian Torp-Pedersen; Gunnar H Gislason
Journal:  Circulation       Date:  2011-05-09       Impact factor: 29.690

7.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

8.  Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

Authors:  Maha Hussain; Catherine M Tangen; Celestia Higano; Paul F Schelhammer; James Faulkner; E David Crawford; George Wilding; Atif Akdas; Eric J Small; Bryan Donnelly; Gary MacVicar; Derek Raghavan
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

9.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.

Authors:  Maha Hussain; Bryan Goldman; Cathy Tangen; Celestia S Higano; Daniel P Petrylak; George Wilding; Atif M Akdas; Eric J Small; Bryan J Donnelly; Subramanian Kanaga Sundram; Patrick A Burch; Robert S Dipaola; E David Crawford
Journal:  J Clin Oncol       Date:  2009-04-20       Impact factor: 44.544

10.  Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Malcolm D Mason; Noel W Clarke; John Anderson; David P Dearnaley; John Dwyer; Gordana Jovic; Alastair W S Ritchie; J Martin Russell; Karen Sanders; George N Thalmann; Gianfilippo Bertelli; Alison J Birtle; Joe M O'Sullivan; Andrew Protheroe; Denise Sheehan; Narayanan Srihari; Mahesh K B Parmar
Journal:  Lancet Oncol       Date:  2012-03-26       Impact factor: 41.316
  10 in total
  1 in total

1.  Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.

Authors:  C-J Ko; S-W Lan; Y-C Lu; T-S Cheng; P-F Lai; C-H Tsai; T-W Hsu; H-Y Lin; H-Y Shyu; S-R Wu; H-H Lin; P-W Hsiao; C-H Chen; H-P Huang; M-S Lee
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.